BMJ:HPV疫苗接种的严重不良事件风险研究

2021-02-01 MedSci原创 MedSci原创

在对50万剂HPV疫苗接种人群的随访研究后发现,没有明确的证据支持HPV疫苗接种可导致严重不良事件风险增加

据统计,2012年,约有63万名女性被诊断为人类乳头瘤病毒(HPV)相关肿瘤,其中53万(84%)为宫颈癌,约26.6万名宫颈癌患者死亡,占全世界女性肿瘤相关死亡的8%。HPV疫苗对降低女性宫颈癌风险有显著作用,WHO建议应对9-14岁女孩优先进行HPV免疫接种,直至2019年,124个国家通过了少女HPV疫苗免疫方案。韩国于2016年6月开始对12-13岁少女进行二价或四价HPV疫苗接种。 在政策实施的第一年,HPV疫苗覆盖率为61.5%,到2018年,这一比例已增加到87.2%。近日研究人员评估了人乳头瘤病毒(HPV)疫苗接种与韩国少女严重不良事件之间的关系。
 
研究人员收集了2017年韩国免疫登记信息系统和国家卫生信息数据库数据,总计收录了441399名11-14岁女孩2017年的疫苗接种信息,其中382020人接种了HPV疫苗,59379人未接种HPV疫苗。研究的主要结果是33种严重的不良事件,包括内分泌、胃肠道、血管、肌肉骨骼、血液学、皮肤学和神经系统疾病。
 
队列分析显示,除偏头痛以外(每10万人-年发病率:接种组vs未接种组为1235.0例 v 920.9例;HR=1.11),其他32个预先确定的严重不良事件均与HPV疫苗接种无关,包括桥本甲状腺炎(每10万人-年发病率:接种组vs未接种组为52.7例vs 36.3例,1.24)和类风湿性关节炎(每10万人-年发病率:接种组vs未接种组为168.1例vs 145.4例,0.99)。采用自我控制风险区间的二次分析证实,HPV疫苗接种与严重不良事件(包括偏头痛)之间没有关联(校正相对风险0.67)。研究结论不受随访期和疫苗亚型的影响。
 
在对50万剂HPV疫苗接种人群的随访研究后发现,没有明确的证据支持HPV疫苗接种可导致严重不良事件风险增加
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849172, encodeId=8dbf18491e2cb, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 29 03:56:58 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055726, encodeId=225d2055e26ff, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Sep 10 23:56:58 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946286, encodeId=7a1d194628681, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Mar 27 06:56:58 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007406, encodeId=d71b200e406ea, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Dec 07 01:56:58 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257928, encodeId=1330125e9284f, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Feb 03 10:56:58 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
    2021-11-29 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849172, encodeId=8dbf18491e2cb, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 29 03:56:58 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055726, encodeId=225d2055e26ff, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Sep 10 23:56:58 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946286, encodeId=7a1d194628681, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Mar 27 06:56:58 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007406, encodeId=d71b200e406ea, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Dec 07 01:56:58 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257928, encodeId=1330125e9284f, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Feb 03 10:56:58 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849172, encodeId=8dbf18491e2cb, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 29 03:56:58 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055726, encodeId=225d2055e26ff, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Sep 10 23:56:58 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946286, encodeId=7a1d194628681, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Mar 27 06:56:58 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007406, encodeId=d71b200e406ea, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Dec 07 01:56:58 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257928, encodeId=1330125e9284f, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Feb 03 10:56:58 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849172, encodeId=8dbf18491e2cb, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 29 03:56:58 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055726, encodeId=225d2055e26ff, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Sep 10 23:56:58 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946286, encodeId=7a1d194628681, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Mar 27 06:56:58 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007406, encodeId=d71b200e406ea, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Dec 07 01:56:58 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257928, encodeId=1330125e9284f, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Feb 03 10:56:58 CST 2021, time=2021-02-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849172, encodeId=8dbf18491e2cb, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 29 03:56:58 CST 2021, time=2021-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055726, encodeId=225d2055e26ff, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Sep 10 23:56:58 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946286, encodeId=7a1d194628681, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Sat Mar 27 06:56:58 CST 2021, time=2021-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007406, encodeId=d71b200e406ea, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Dec 07 01:56:58 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257928, encodeId=1330125e9284f, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Wed Feb 03 10:56:58 CST 2021, time=2021-02-03, status=1, ipAttribution=)]

相关资讯

高危型HPV-18感染可增加口腔癌患者患上第二恶性口腔肿瘤的机会

  根据台湾的研究结果,约三分之一的口腔鳞状细胞癌(OSCC)的病人由人类乳头状瘤病毒(HPV)感染导致,而其中高危HPV感染为四分之三左右。同时研究表明,HPV变种HPV-18的感染较其他未变异的同属病毒更能有效的导致病人继发性的恶性肿瘤的发生。   研究者同时指出,因为病人纳入数量有限,研究结果仍需要大样本的研究去进一步明确。然而,对于“高危HPV-18的感染在继发性恶性肿瘤的发生中产生重要